Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence

REFERENCES

• McCance-Katz EF, Mandell TW. Drug interactions of clinical importance with methadone and buprenorphine. Am J Addict 2010; 19(1):2–3.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5):563–572.
   PubMed Web of Science ®Google Scholar
• Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend 2001; 64(2):233–241.
   PubMed Web of Science ®Google Scholar
• Farre M, Teran MT, Roset PN, Mas M, Torrens M, Cami J. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology (Berl) 1998; 140(4):486–495.
   PubMed Web of Science ®Google Scholar
• Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry 2000; 176:285–289.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Adelson M. Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT). Eur Neuropsychopharmacol 2008; 18(3):188–193.
   PubMed Web of Science ®Google Scholar
• Carpenter KM, Brooks AC, Vosburg SK, Nunes EV. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: A controlled clinical trial. Drug Alcohol Depend 2004; 74(2):123–134.
   PubMed Web of Science ®Google Scholar
• Hamilton SP, Klimchak C, Nunes EV. Treatment of depressed methadone maintenance patients with nefazodone. A case series. Am J Addict 1998; 7(4):309–312.
   PubMed Web of Science ®Google Scholar
• Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 1998; 50(3):221–226.
   PubMed Web of Science ®Google Scholar
• Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, Eap CB. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol 2007; 27(3):273–278.
   PubMed Web of Science ®Google Scholar
• Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: Application in the management of cancer pain. Pain 1988; 33(3):313–322.
   PubMed Web of Science ®Google Scholar
• Wedekind D, Jacobs S, Karg I, Luedecke C, Schneider U, Cimander K, Baumann P, Ruether E, Poser W, Havemann-Reinecke U. Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone. World J Biol Psychiatry 2008; 9:1–10.
   Google Scholar
• Ball JC, Corty E, Erdlen DL, Nurco DN. Major patterns of polydrug abuse among heroin addicts. NIDA Res Monogr 1986; 67:256–262.
   PubMedGoogle Scholar
• Darke S, Swift W, Hall W. Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. Addiction 1994; 89(2):211–217.
   PubMed Web of Science ®Google Scholar
• Stitzer ML, Griffiths RR, McLellan AT, Grabowski J, Hawthorne JW. Diazepam use among methadone maintenance patients: Patterns and dosages. Drug Alcohol Depend 1981; 8(3):189–199.
   PubMed Web of Science ®Google Scholar
• Grass H, Behnsen S, Kimont HG, Staak M, Kaferstein H. Methadone and its role in drug-related fatalities in Cologne 1989–2000. Forensic Sci Int 2003; 132(3):195–200.
   PubMed Web of Science ®Google Scholar
• Darke S, Duflou J, Kaye S. Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims. Addiction 2007; 102(11):1793–1797.
   PubMed Web of Science ®Google Scholar
• Kintz P. Deaths involving buprenorphine: A compendium of French cases. Forensic Sci Int 2001; 121(1–2):65–69.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: Benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 1999; 19(4):533–552.
   PubMed Web of Science ®Google Scholar
• Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43(Suppl. 4):S216–S223.
   PubMed Web of Science ®Google Scholar
• Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003; 31(6):742–747.
   PubMed Web of Science ®Google Scholar
• Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108(3): 363–374.
   PubMed Web of Science ®Google Scholar
• Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22(2):211–215.
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9(2):365–373.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56(2): PL45–PL50.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16(1):36–44.
   PubMed Web of Science ®Google Scholar
• Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008; 121(1):66–71.
   PubMed Web of Science ®Google Scholar
• Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol 2010; 28(1):19–22.
   PubMed Web of Science ®Google Scholar
• Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos 2005; 33(5):689–695.
   PubMed Web of Science ®Google Scholar
• Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002; 306(1):31–39.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26(8):818–821.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 1999; 27(10):1165–1170.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Radominska-Pandya A, Tephly TR. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch Biochem Biophys 1998; 356(2):301–305.
   PubMed Web of Science ®Google Scholar
• Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998; 26(6):507–512.
   PubMed Web of Science ®Google Scholar
• Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25(1):1–4.
   PubMed Web of Science ®Google Scholar
• Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26(1):73–77.
   PubMed Web of Science ®Google Scholar
• King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, Tephly TR. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 1996; 332(1):92–100.
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 2009; 3(2): 101–107.
   PubMedGoogle Scholar
• Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010; 38(1):40–45.
   PubMed Web of Science ®Google Scholar
• Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 2002; 25(5):682–685.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 2003; 31(6):768–772.
   PubMed Web of Science ®Google Scholar
• Verebey K. The clinical pharmacology of naltrexone: Pharmacology and pharmacodynamics. NIDA Res Monogr 1981; 28:147–158.
   PubMedGoogle Scholar
• Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35(3):192–213.
   PubMed Web of Science ®Google Scholar
• Porter SJ, Somogyi AA, White JM. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 2000; 50(5):465–471.
   PubMed Web of Science ®Google Scholar
• Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985; 38(4):419–422.
   PubMed Web of Science ®Google Scholar
• Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, Morley JE. Naltrexone hydrochloride (Trexan): A review of serum transaminase elevations at high dosage. NIDA Res Monogr 1986; 67:66–72.
   PubMedGoogle Scholar
• Maany I, O'Brien CP, Woody G. Interaction between thioridazine and naltrexone. Am J Psychiatry 1987; 144(7):966.
   PubMed Web of Science ®Google Scholar
• Otani K. Cytochrome P450 3A4 and benzodiazepines. Seishin Shinkeigaku Zasshi 2003; 105(5):631–642.
   PubMedGoogle Scholar
• Donato MT, Hallifax D, Picazo L, Castell JV, Houston JB, Gomez-Lechon MJ, Lahoz A. Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam and midazolam in adenoviral P450 transfected HepG2 cells, and comparison with hepatocytes and in vivo. Drug Metab Dispos 2010; 38(9):1449–1455.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993; 47(4):268–276.
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38(2):131–137.
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32(3):210–258.
   PubMed Web of Science ®Google Scholar
• Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11(Suppl. 5):31–61.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 1998; 18(3):256.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend 2007; 91(2–3):187–194.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006; 26(3):274–283.
   PubMed Web of Science ®Google Scholar
• Preston KL, Griffiths RR, Stitzer ML, Bigelow GE, Liebson IA. Diazepam and methadone interactions in methadone maintenance. Clin Pharmacol Ther 1984; 36(4):534–541.
   PubMed Web of Science ®Google Scholar
• Ernst E, Bartu A, Popescu A, Ileutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993–99. Aust N Z J Public Health 2002; 26(4):364–370.
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41(14):1153–1193.
   PubMed Web of Science ®Google Scholar
• Preston KL, Griffiths RR, Cone EJ, Darwin WD, Gorodetzky CW. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend 1986; 18(2):195–202.
   PubMed Web of Science ®Google Scholar
• Pond SM, Tong TG, Benowitz NL, Jacob P, III, Rigod J. Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin Pharmacol Ther 1982; 31(2):139–143.
   PubMed Web of Science ®Google Scholar
• Borron SW, Monier C, Risede P, Baud FJ. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 2002; 21(11):599–605.
   PubMed Web of Science ®Google Scholar
• Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997; 60(22):1953–1964.
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur J Clin Pharmacol 2005; 60(12):875–881.
   PubMed Web of Science ®Google Scholar
• Bomsien S, Aderjan R, Mattern R, Skopp G. Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes. Eur J Clin Pharmacol 2006; 62(8):639–643.
   PubMed Web of Science ®Google Scholar
• Gueye PN, Borron SW, Risede P, Monier C, Buneaux F, Debray M, Baud FJ. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002; 65(1):107–114.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am J Drug Alcohol Abuse 2008; 34(4):511–517.
   PubMed Web of Science ®Google Scholar
• Ng WL, Mythily S, Song G, Chan YH, Winslow M. Concomitant use of midazolam and buprenorphine and its implications among drug users in Singapore. Ann Acad Med Singapore 2007; 36(9):774–777.
   PubMed Web of Science ®Google Scholar
• Gueye PN, Megarbane B, Borron SW, Adnet F, Galliot-Guilley M, Ricordel I, Tourneau J, Goldgran-Toledano D, Baud FJ. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995–1999. Addiction 2002; 97(10):1295–304.
   Google Scholar
• Druid H, Holmgren P, Ahlner J. Flunitrazepam: An evaluation of use, abuse and toxicity. Forensic Sci Int 2001; 122(2–3):136–141.
   PubMed Web of Science ®Google Scholar
• Ibrahim RB, Wilson JG, Thorsby ME, Edwards DJ. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sci 2000; 66(14):1293–1298.
   PubMed Web of Science ®Google Scholar
• Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am J Psychiatry 2000; 157(7):1164–1166.
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos 2001; 29(2):133–140.
   PubMed Web of Science ®Google Scholar
• Megarbane B, Pirnay S, Borron SW, Trout H, Monier C, Risede P, Boschi G, Baud FJ. Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicol Lett 2005; 157(3):211–219.
   PubMed Web of Science ®Google Scholar
• Pirnay S, Megarbane B, Decleves X, Risede P, Borron SW, Bouchonnet S, Perrin B, Debray M, Milan N, Duarte T, Ricordel I, Baud FJ. Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicol Sci 2008; 106(1):64–73.
   PubMed Web of Science ®Google Scholar
• Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. J Anal Toxicol 1998; 22(6):430–434.
   PubMed Web of Science ®Google Scholar
• Boyd J, Randell T, Luurila H, Kuisma M. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003; 47(8):1031–1033.
   PubMed Web of Science ®Google Scholar
• Pirnay SO, Megarbane B, Borron SW, Risede P, Monier C, Ricordel I, Baud FJ. Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats. Basic Clin Pharmacol Toxicol 2008; 103(3):228–239.
   PubMed Web of Science ®Google Scholar
• Sekar M, Mimpriss TJ. Buprenorphine, benzodiazepines and prolonged respiratory depression. Anaesthesia 1987; 42(5):567–568.
   PubMed Web of Science ®Google Scholar
• Swift R, Davidson D, Rosen S, Fitz E, Camara P. Naltrexone effects on diazepam intoxication and pharmacokinetics in humans. Psychopharmacology (Berl) 1998; 135(3):256–262.
   PubMed Web of Science ®Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr Drug Metab 2002; 3(1):13–37.
   PubMed Web of Science ®Google Scholar
• Mourilhe P, Stokes PE. Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression. Drug Saf 1998; 18(1):57–82.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85(1):11–28.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999; 19(5 Suppl. 1):23S–35S.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: Role of human cytochromes P450. J Clin Psychiatry 1998; 59(Suppl. 15): 19–27.
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Effects of antidepressants on the cytochrome P450 system. Am J Psychiatry 1996; 153(12):1655–1657.
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(Suppl. 1):1–21.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry 1986; 43(8): 733–738.
   PubMed Web of Science ®Google Scholar
• Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997; 17(2):113–117.
   PubMed Web of Science ®Google Scholar
• Iribarne C, Picart D, Dreano Y, Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 1998; 12(2): 194–199.
   PubMed Web of Science ®Google Scholar
• Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): Application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 2003; 24(15):2577–2587.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80(6):668–681.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78(6):593–604.
   PubMed Web of Science ®Google Scholar
• Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997; 117(1):13–23.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. CYP2C9 is a principal low-affinity phenacetin O-deethylase: Fluvoxamine is not a specific CYP1A2 inhibitor. Drug Metab Dispos 1999; 27(12):1519–1522.
   PubMed Web of Science ®Google Scholar
• Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994; 16(1):42–45.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006; 43(Suppl. 4): S224–S234.
   PubMed Web of Science ®Google Scholar
• Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003; 17(5):517–538.
   PubMed Web of Science ®Google Scholar
• Mulsant BH, Foglia JP, Sweet RA, Rosen J, Lo KH, Pollock BG. The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol 1997; 17(4):318–321.
   PubMed Web of Science ®Google Scholar
• Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos 1999; 27(9):1078–1084.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41(3):181–186.
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37(3):177–193.
   PubMed Web of Science ®Google Scholar
• Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999; 9(4):301–309.
   PubMed Web of Science ®Google Scholar
• DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 2001; 40(7): 509–522.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Kenna GA. Quetiapine: Treatment for substance abuse and drug of abuse. Am J Health Syst Pharm 2008; 65(7):611–618.
   PubMed Web of Science ®Google Scholar
• Bano MD, Mico JA, Agujetas M, Lopez ML, Guillen JL. Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels. Actas Esp Psiquiatr 2001; 29(4):215–220.
   PubMed Web of Science ®Google Scholar
• Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14(11):747–753.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11(1):44–49.
   PubMed Web of Science ®Google Scholar
• Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95(7):915–918.
   PubMed Web of Science ®Google Scholar
• Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, Takahashi J, Ishida N, Horie M, Kunugi H. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(2):401–405.
   PubMed Web of Science ®Google Scholar
• Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59(Suppl. 15):42–48.
   PubMed Web of Science ®Google Scholar
• Ohtani H, Odagiri Y, Sato H, Sawada Y, Iga T. A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea pigs. Biol Pharm Bull 2001; 24(5):550–554.
   PubMed Web of Science ®Google Scholar
• Acikalin A, Satar S, Avc A, Topal M, Kuvandk G, Sebe A. QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. Am J Ther 17(1):30–33.
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004; 45(5):371–377.
   PubMed Web of Science ®Google Scholar
• Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89(11):1363–1372.
   PubMed Web of Science ®Google Scholar
• Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310(6974):221–224.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999; 19(4):511–532.
   PubMed Web of Science ®Google Scholar
• Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47(11):1969–1979.
   PubMed Web of Science ®Google Scholar
• Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990; 83(8):981.
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61(3):246–255.
   PubMed Web of Science ®Google Scholar
• Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31(3):198–214.
   PubMed Web of Science ®Google Scholar
• Kuhn KL, Halikas JA, Kemp KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr 1989; 95:316–317.
   PubMedGoogle Scholar
• Benitez-Rosario MA, Salinas Martin A, Gomez-Ontanon E, Feria M. Methadone-induced respiratory depression after discontinuing carbamazepine administration. J Pain Symptom Manage 2006; 32(2):99–100.
   PubMed Web of Science ®Google Scholar
• Kristensen O, Lolandsmo T, Isaksen A, Vederhus JK, Clausen T. Treatment of polydrug-using opiate dependents during withdrawal: Towards a standardisation of treatment. BMC Psychiatry 2006; 6:54.
   PubMed Web of Science ®Google Scholar
• Kleber HD, Gold MS. Use of psychotropic drugs in treatment of methadone maintained narcotic addicts. Ann N Y Acad Sci 1978; 311:81–98.
   PubMedGoogle Scholar
• Chen Y, Kelton CM, Jing Y, Guo JJ, Li X, Patel NC. Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res Social Adm Pharm 2008; 4(3):244–257.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151(6):737–748.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5(1):6–13.
   PubMed Web of Science ®Google Scholar
• Cohen MJ, Hanbury R, Stimmel B. Abuse of amitriptyline. JAMA 1978; 240(13):1372–1373.
   PubMed Web of Science ®Google Scholar
• Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry 1989; 146(12): 1611–1613.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Wodak A, Day RO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet 1997; 33(5):344–400.
   PubMed Web of Science ®Google Scholar
• Richelson E. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72(9):835–847.
   PubMed Web of Science ®Google Scholar
• Liu SJ, Wang RI. Increased analgesia and alterations in distribution and metabolism of methadone by desipramine in the rat. J Pharmacol Exp Ther 1975; 195(1):94–104.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95(4):434–441.
   PubMed Web of Science ®Google Scholar
• El-Ganzouri AR, Ivankovich AD, Braverman B, McCarthy R. Monoamine oxidase inhibitors: Should they be discontinued preoperatively? Anesth Analg 1985; 64(6):592–596.
   PubMed Web of Science ®Google Scholar
• Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ. Cardiac surgery in a patient taking monoamine oxidase inhibitors: An adverse fentanyl reaction. Anesth Analg 1994; 78(3):593–597.
   PubMed Web of Science ®Google Scholar
• Michaels I, Serrins M, Shier NQ, Barash PG. Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors. Anesth Analg 1984; 63(11):1041–1044.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Serotonin syndrome: History and risk. Fundam Clin Pharmacol 1998; 12(5):482–491.
   PubMed Web of Science ®Google Scholar